Table 2.
Adjuvant therapy after surgical resection
| Substage category | Treatment category | ||||||
|---|---|---|---|---|---|---|---|
| Total | Stage IIIA | Stage IIIB/C/D | P-value | Anti-PD1 | BRAF/MEK | P-value | |
| N = 507 | N = 168 | N = 339 | N = 360 | N = 45 | |||
| Adjuvant therapy, n (%) | - | ||||||
| Pembrolizumab | 222 (54.8) | 62 (48.4) | 160 (57.8) | 222 (61.7) | 0 (0.0) | - | |
| Nivolumab | 138 (34.1) | 50 (39.1) | 88 (31.8) | 138 (38.3) | 0 (0.0) | - | |
| Dabrafenib | 45 (11.1) | 16 (12.5) | 29 (10.5) | 0 (0.0) | 45 (100.0) | - | |
| Trametinib | 45 (11.1) | 16 (12.5) | 29 (10.5) | 0 (0.0) | 45 (100.0) | 0.41 | |
| Time from resection to treatment initiation (days) (N = 350)a, mean ± SD [median] |
36.9 ± 32.5 [30.0] |
33.1 ± 27.0 [28.0] |
38.6 ± 34.6 [30.0] |
0.15 |
37.7 ± 33.9 [30.0] |
29.7 ± 16.3 [27.0] |
1.00 |
| Patients who discontinued treatment (N = 329), n (%)a | 258 (78.4) | 82 (80.4) | 176 (77.5) | 0.66 | 231 (78.3) | 27 (79.4) | 0.98 |
| Duration of AT (days) (N = 258)a, mean ± SD [median] |
327.8 ± 138.5 [357.0] |
332.8 ± 141.0 [357.0] |
325.6 ± 137.6 [355.0] |
0.58 |
328.0 ± 141.6 [357.0] |
326.1 ± 110.5 [357.0] |
1.00 |
| Patients with changes in adjuvant treatment, n (%) | 25 (6.2) | 5 (3.9) | 20 (7.2) | 0.29 | 23 (6.4) | 2 (4.4) | |
Abbreviations: AT adjuvant therapy, SD standard deviation
aTotal number of patients with available information